Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Unaudited NAV for May 2023
Unaudited NAV for May 2023
Unaudited NAV for May 2023
Correction: Result of Annual General Meeting
Correction: Result of Annual General Meeting
Correction: Result of Annual General Meeting
Result of Annual General Meeting
Result of Annual General Meeting
Result of Annual General Meeting
Portfolio company Ensoma announces closing of Series B Extension
Portfolio company Ensoma announces closing of Series B Extension
Portfolio company Ensoma announces closing of Series B Extension
Unaudited NAV for April 2023
Unaudited NAV for April 2023
Unaudited NAV for April 2023
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Arix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Financial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
Full Year results now to be released on 25 April 2023
Full Year results now to be released on 25 April 2023
Full Year results now to be released on 25 April 2023
Unaudited NAV for March 2023
Unaudited NAV for March 2023
Unaudited NAV for March 2023
Notice of Results and Investor Presentation
Notice of Results and Investor Presentation
Notice of Results and Investor Presentation
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
Portfolio company Harpoon Therapeutics announces closing of $25 million private placement
Form 8.3 - Maitland Institutional Services Limited: Re Reabold Resources Plc
Form 8.3 - Maitland Institutional Services Limited: Re Reabold Resources Plc
Form 8.3 - Maitland Institutional Services Limited: Re Reabold Resources Plc
Unaudited NAV for February 2023
Unaudited NAV for February 2023
Unaudited NAV for February 2023
Portfolio company Disc Medicine announces $62.5 million financing
Portfolio company Disc Medicine announces $62.5 million financing
Portfolio company Disc Medicine announces $62.5 million financing
Unaudited NAV for January 2023
Unaudited NAV for January 2023
Unaudited NAV for January 2023
Unaudited NAV for December 2022
Unaudited NAV for December 2022
Unaudited NAV for December 2022
Board Change
Board Change
Board Change
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Portfolio company Twelve Bio to be acquired alongside $85 million financing of Ensoma
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Portfolio Company Disc Medicine Completes Merger with Gemini Therapeutics
Unaudited NAV for November 2022
Unaudited NAV for November 2022
Unaudited NAV for November 2022
Arix to Present at Mello Investment Trusts & Funds
Arix to Present at Mello Investment Trusts & Funds
Arix to Present at Mello Investment Trusts & Funds
Unaudited NAV for October 2022
Unaudited NAV for October 2022
Unaudited NAV for October 2022
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics
Unaudited NAV for September 2022
Unaudited NAV for September 2022
Unaudited NAV for September 2022